Curriculum
2.00 CME Credit
The Future of Alzheimer Disease: Early Recognition and Emerging Therapy
This comprehensive curriculum will equip you with the knowledge you need to earlier recognize, accurately diagnose, and appropriately treat patients with Alzheimer disease (AD). Across an array of formats, you will hear experts discuss strategies to mitigate the devastating effects of this progressive disease on patients and those who care for them. Finally, this education will leave you feeling optimistic about the exciting changes on the horizon for AD, including the emergence of potentially disease-modifying treatments, offering hope to clinicians and patients alike.
CME Information
2.00 AMA PRA Category 1 Credits™, 2.00 ABIM MOC or 2.10 AANP, including 0.98 AANP Pharm
Release Date: 5/23/2022
Available for credit until 9/20/2023
Learning Objectives
- Discuss strategies to promote the early detection of mild cognitive impairment (MCI) or dementia in appropriate patients
- Review the diagnosis of Alzheimer Disease
- Explore the mechanism of action and evidence supporting new and emerging disease-modifying therapies for Alzheimer disease (AD)
- Consider which patients are most likely to benefit from these new and emerging disease-modifying therapies
- Examine the diagnosis of Alzheimer disease (AD) and MCI due to AD, including the emerging role of biomarkers
- Explore the evidence supporting new and emerging disease-modifying therapies for AD and consider which patients are most likely to benefit from these therapies
Courses
Podcast
Why Is Early Detection of Alzheimer Disease So Important?
0.25 CME/MOC
0.30 AANP
Podcast
New and Emerging Therapies for Alzheimer Disease: Anti-Amyloid Therapies
0.25 CME/MOC
0.23 AANP | 0.23 Pharmacology
Interactive Learning
Early Detection and Diagnosis of Alzheimer Disease
0.50 CME/MOC
0.53 AANP
Interactive Learning
New and Emerging Therapies for Alzheimer Disease
0.50 CME/MOC
0.50 AANP | 0.50 Pharmacology
Podcast
Addressing Clinicians’ Challenges and Misinformation Around Diagnosis of Alzheimer Disease
0.25 CME/MOC
0.29 AANP
Podcast
Addressing Clinicians’ Challenges and Misinformation Around New and Emerging Treatments for Alzheimer Disease
0.25 CME/MOC
0.25 AANP | 0.25 Pharmacology
Faculty
Daniel Press, MD
Chief, Division of Cognitive Neurology
Associate Professor of Neurology,
Harvard Medical School
Boston, MA
Marwan N. Sabbagh, MD, FAAN
Professor of Neurology, Alzheimer's and Memory Disorders Division
Barrow Neurological Institute
Research Professor, University of Arizona College of Medicine-Phoenix
Clinical Professor of Neurology, Creighton University
Gad A. Marshall, MD
Associate Professor of Neurology
Harvard Medical School
Associate Medical Director of Clinical Trials
Center for Alzheimer Research and Treatment
Brigham and Women's Hospital
Assistant in Neurology
Massachusetts General Hospital
Boston, MA
CME Information
AMA PRA Category 1 Credits™
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and American Kidney Fund. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this endured activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and American Kidney Fund. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
This activity is approved for 1.56 contact hour of continuing education, which includes 0.73 hour of pharmacology.
Supporters and Partners
Commercial Supporter
This activity is supported by an educational grant from Lilly
Education Partner
Pri-Med Institute
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Pri-Med Institute and Vindico Medical Education staff have no relevant financial relationships to disclose.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.